Skip to main content
Erschienen in: International Journal of Clinical Oncology 3/2017

01.06.2017 | Original Article

Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy

verfasst von: Masashi Matsushima, Eiji Kikuchi, Hirotaka Akita, Akira Miyajima, Mototsugu Oya, Masahiro Jinzaki

Erschienen in: International Journal of Clinical Oncology | Ausgabe 3/2017

Einloggen, um Zugang zu erhalten

Abstract

Background

Detailed information is not currently available on the incidence, natural course, and management of asymptomatic abnormal prostate findings incidentally detected by radiologic evaluations after BCG therapy for non-muscle-invasive bladder cancer patients.

Methods

We identified 38 patients who were evaluated by contrast-enhanced CT scans before TUR-BT and after BCG therapy between 2006 and 2012. We evaluated the clinical courses of patients with abnormal radiologic findings of the prostate gland after BCG therapy.

Results

Abnormal findings on CT scans were found in the prostate glands of 11 of the 38 patients examined (28.9%), none of whom exhibited any sign or symptom associated with prostatitis. Abnormal findings included a low attenuation area (n = 6, 15.8%), contrast enhancement (n = 3, 7.9%), and a low attenuation area and contrast enhancement in the prostate gland (n = 2, 5.3%). During the follow-up, abnormal prostate findings disappeared spontaneously in most cases without any anti-bacterial or anti-tuberculous drug treatments. No significant differences were observed in patient clinical backgrounds, with the exception of post-BCG prostate volumes, between patients with and without abnormal CT findings. Furthermore, no significant differences were noted in the incidence of the adverse effects of BCG therapy, tumor recurrence rates, or progression rates between patients with and without abnormal CT findings of the prostate gland after BCG therapy.

Conclusions

Asymptomatic abnormal prostate findings incidentally detected by CT after BCG therapy are not rare, and these disappear over time during the follow-up period without any treatment.
Literatur
1.
Zurück zum Zitat Lamm DL, Stogdill VD, Stogdill BJ et al (1986) Complications of bacillus Calmette–Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135(2):272–274PubMed Lamm DL, Stogdill VD, Stogdill BJ et al (1986) Complications of bacillus Calmette–Guerin immunotherapy in 1,278 patients with bladder cancer. J Urol 135(2):272–274PubMed
2.
Zurück zum Zitat Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183PubMed Morales A, Eidinger D, Bruce AW (1976) Intracavitary bacillus Calmette–Guerin in the treatment of superficial bladder tumors. J Urol 116(2):180–183PubMed
3.
Zurück zum Zitat Ma W, Kang SK, Hricak H et al (2009) Imaging appearance of granulomatous disease after intravesical bacille Calmette–Guerin (BCG) treatment of bladder carcinoma. Am J Roentgenol 192(6):1494–1500CrossRef Ma W, Kang SK, Hricak H et al (2009) Imaging appearance of granulomatous disease after intravesical bacille Calmette–Guerin (BCG) treatment of bladder carcinoma. Am J Roentgenol 192(6):1494–1500CrossRef
4.
Zurück zum Zitat Suzuki T, Takeuchi M, Naiki T et al (2013) MRI findings of granulomatous prostatitis developing after intravesical bacillus Calmette–Guerin therapy. Clin Radiol 68(6):595–599CrossRefPubMed Suzuki T, Takeuchi M, Naiki T et al (2013) MRI findings of granulomatous prostatitis developing after intravesical bacillus Calmette–Guerin therapy. Clin Radiol 68(6):595–599CrossRefPubMed
5.
Zurück zum Zitat Luftenegger W, Ackermann DK, Futterlieb A et al (1996) Intravesical versus intravesical plus intradermal bacillus Calmette–Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155(2):483–487CrossRefPubMed Luftenegger W, Ackermann DK, Futterlieb A et al (1996) Intravesical versus intravesical plus intradermal bacillus Calmette–Guerin: a prospective randomized study in patients with recurrent superficial bladder tumors. J Urol 155(2):483–487CrossRefPubMed
6.
Zurück zum Zitat Suzuki S, Shinohara N, Harabayashi T et al (2002) Complications of bacillus Calmette–Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 7(5):289–293PubMed Suzuki S, Shinohara N, Harabayashi T et al (2002) Complications of bacillus Calmette–Guerin therapy in superficial urothelial cancer: clinical analysis and implications. Int J Clin Oncol 7(5):289–293PubMed
7.
Zurück zum Zitat Jallad S, Goubet S, Symes A et al (2014) Prognostic value of inflammation or granuloma after intravesical BCG in non-muscle-invasive bladder cancer. BJU Int 113(5b):E22–E27CrossRefPubMed Jallad S, Goubet S, Symes A et al (2014) Prognostic value of inflammation or granuloma after intravesical BCG in non-muscle-invasive bladder cancer. BJU Int 113(5b):E22–E27CrossRefPubMed
8.
Zurück zum Zitat Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2003) The side effects of bacillus Calmette–Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):423–428CrossRefPubMed Sylvester RJ, van der Meijden AP, Oosterlinck W et al (2003) The side effects of bacillus Calmette–Guerin in the treatment of Ta T1 bladder cancer do not predict its efficacy: results from a European Organisation for Research and Treatment of Cancer Genito-Urinary Group Phase III Trial. Eur Urol 44(4):423–428CrossRefPubMed
9.
Zurück zum Zitat Bassi P, Milani C, Meneghini A et al (1992) Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 40(2):175–179CrossRefPubMed Bassi P, Milani C, Meneghini A et al (1992) Clinical value of pathologic changes after intravesical BCG therapy of superficial bladder cancer. Urology 40(2):175–179CrossRefPubMed
10.
Zurück zum Zitat Pieras-Ayala E, Palou-Redorta J, Tomero-Ruiz JI et al (2001) Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol 33(3):469–472CrossRefPubMed Pieras-Ayala E, Palou-Redorta J, Tomero-Ruiz JI et al (2001) Prognostic value of cystocopically pseudotumoral lesions (inflammation/granuloma) in primary stage T1 grade 3 bladder tumors treated with BCG. Int Urol Nephrol 33(3):469–472CrossRefPubMed
11.
Zurück zum Zitat Torrence RJ, Kavoussi LR, Catalona WJ et al (1988) Prognostic factors in patients treated with intravesical bacillus Calmette–Guerin for superficial bladder cancer. J Urol 139(5):941–944PubMed Torrence RJ, Kavoussi LR, Catalona WJ et al (1988) Prognostic factors in patients treated with intravesical bacillus Calmette–Guerin for superficial bladder cancer. J Urol 139(5):941–944PubMed
12.
Zurück zum Zitat Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653CrossRefPubMed Babjuk M, Burger M, Zigeuner R et al (2013) EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 64(4):639–653CrossRefPubMed
13.
Zurück zum Zitat Jinzaki M, Kikuchi E, Akita H et al (2016) Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol 23(4):284–298CrossRefPubMed Jinzaki M, Kikuchi E, Akita H et al (2016) Role of computed tomography urography in the clinical evaluation of upper tract urothelial carcinoma. Int J Urol 23(4):284–298CrossRefPubMed
14.
Zurück zum Zitat Jinzaki M, Tanimoto A, Shinmoto H et al (2007) Detection of bladder tumors with dynamic contrast-enhanced MDCT. Am J Roentgenol 188(4):913–918CrossRef Jinzaki M, Tanimoto A, Shinmoto H et al (2007) Detection of bladder tumors with dynamic contrast-enhanced MDCT. Am J Roentgenol 188(4):913–918CrossRef
15.
Zurück zum Zitat Takeda T, Kikuchi E, Yuge K et al (2009) Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 73(6):1318–1322CrossRefPubMed Takeda T, Kikuchi E, Yuge K et al (2009) Discontinuance of bacille Calmette-Guerin instillation therapy for nonmuscle-invasive bladder cancer has negative effect on tumor recurrence. Urology 73(6):1318–1322CrossRefPubMed
16.
Zurück zum Zitat Miyashita H, Troncoso P, Babaian RJ (1992) BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. Urology 39(4):364–367CrossRefPubMed Miyashita H, Troncoso P, Babaian RJ (1992) BCG-induced granulomatous prostatitis: a comparative ultrasound and pathologic study. Urology 39(4):364–367CrossRefPubMed
17.
Zurück zum Zitat Rubenstein JB, Swayne LC, Magidson JG et al (1991) Granulomatous prostatitis: a hypoechoic lesion of the prostate. Urol Radiol 13(2):119–122CrossRefPubMed Rubenstein JB, Swayne LC, Magidson JG et al (1991) Granulomatous prostatitis: a hypoechoic lesion of the prostate. Urol Radiol 13(2):119–122CrossRefPubMed
18.
Zurück zum Zitat Logan JK, Walton-Diaz A, Rais-Bahrami S et al (2014) Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical bacillus Calmette–Guerin therapy. J Comput Assist Tomogr 38(2):274–276CrossRefPubMedPubMedCentral Logan JK, Walton-Diaz A, Rais-Bahrami S et al (2014) Changes observed in multiparametric prostate magnetic resonance imaging characteristics correlate with histopathological development of chronic granulomatous prostatitis after intravesical bacillus Calmette–Guerin therapy. J Comput Assist Tomogr 38(2):274–276CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Andius P, Holmang S (2004) Bacillus Calmette–Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93(7):980–984CrossRefPubMed Andius P, Holmang S (2004) Bacillus Calmette–Guerin therapy in stage Ta/T1 bladder cancer: prognostic factors for time to recurrence and progression. BJU Int 93(7):980–984CrossRefPubMed
20.
Zurück zum Zitat Oates RD, Stilmant MM, Freedlund MC et al (1988) Granulomatous prostatitis following bacillus Calmette–Guerin immunotherapy of bladder cancer. J Urol 140(4):751–754PubMed Oates RD, Stilmant MM, Freedlund MC et al (1988) Granulomatous prostatitis following bacillus Calmette–Guerin immunotherapy of bladder cancer. J Urol 140(4):751–754PubMed
21.
Zurück zum Zitat Rischmann P, Desgrandchamps F, Malavaud B et al (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(suppl 1):33–36CrossRefPubMed Rischmann P, Desgrandchamps F, Malavaud B et al (2000) BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37(suppl 1):33–36CrossRefPubMed
22.
23.
Zurück zum Zitat LaFontaine PD, Middleman BR, Graham SD Jr et al (1997) Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 49(3):363–366CrossRefPubMed LaFontaine PD, Middleman BR, Graham SD Jr et al (1997) Incidence of granulomatous prostatitis and acid-fast bacilli after intravesical BCG therapy. Urology 49(3):363–366CrossRefPubMed
24.
Zurück zum Zitat Mukamel E, Konichezky M, Engelstein D et al (1990) Clinical and pathological findings in prostates following intravesical bacillus Calmette–Guerin instillations. J Urol 144(6):1399–1400PubMed Mukamel E, Konichezky M, Engelstein D et al (1990) Clinical and pathological findings in prostates following intravesical bacillus Calmette–Guerin instillations. J Urol 144(6):1399–1400PubMed
25.
Zurück zum Zitat Alexander RB, Mann DL, Borkowski AA et al (2004) Granulomatous prostatitis linked to HLA-DRB1*1501. J Urol 171(6 pt 1):2326–2329CrossRefPubMed Alexander RB, Mann DL, Borkowski AA et al (2004) Granulomatous prostatitis linked to HLA-DRB1*1501. J Urol 171(6 pt 1):2326–2329CrossRefPubMed
26.
Zurück zum Zitat Balasar M, Dogan M, Kandemir A et al (2014) Investigation of granulomatous prostatitis incidence following intravesical BCG therapy. Int J Clin Exp Med 7(6):1554–1557PubMedPubMedCentral Balasar M, Dogan M, Kandemir A et al (2014) Investigation of granulomatous prostatitis incidence following intravesical BCG therapy. Int J Clin Exp Med 7(6):1554–1557PubMedPubMedCentral
27.
Zurück zum Zitat Stillwell TJ, Engen DE, Farrow GM (1987) The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 138(2):320–323PubMed Stillwell TJ, Engen DE, Farrow GM (1987) The clinical spectrum of granulomatous prostatitis: a report of 200 cases. J Urol 138(2):320–323PubMed
28.
Zurück zum Zitat Kamat AM, Hegarty PK, Gee JR et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63(1):4–15CrossRefPubMed Kamat AM, Hegarty PK, Gee JR et al (2013) ICUD-EAU International Consultation on Bladder Cancer 2012: screening, diagnosis, and molecular markers. Eur Urol 63(1):4–15CrossRefPubMed
29.
Zurück zum Zitat Jinzaki M, Matsumoto K, Kikuchi E et al (2011) Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. Am J Roentgenol 196(5):1102–1109CrossRef Jinzaki M, Matsumoto K, Kikuchi E et al (2011) Comparison of CT urography and excretory urography in the detection and localization of urothelial carcinoma of the upper urinary tract. Am J Roentgenol 196(5):1102–1109CrossRef
Metadaten
Titel
Natural course of asymptomatic abnormal prostate findings incidentally detected by CT after intravesical BCG therapy
verfasst von
Masashi Matsushima
Eiji Kikuchi
Hirotaka Akita
Akira Miyajima
Mototsugu Oya
Masahiro Jinzaki
Publikationsdatum
01.06.2017
Verlag
Springer Japan
Erschienen in
International Journal of Clinical Oncology / Ausgabe 3/2017
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-017-1096-z

Weitere Artikel der Ausgabe 3/2017

International Journal of Clinical Oncology 3/2017 Zur Ausgabe

Alphablocker schützt vor Miktionsproblemen nach der Biopsie

16.05.2024 alpha-1-Rezeptorantagonisten Nachrichten

Nach einer Prostatabiopsie treten häufig Probleme beim Wasserlassen auf. Ob sich das durch den periinterventionellen Einsatz von Alphablockern verhindern lässt, haben australische Mediziner im Zuge einer Metaanalyse untersucht.

Antikörper-Wirkstoff-Konjugat hält solide Tumoren in Schach

16.05.2024 Zielgerichtete Therapie Nachrichten

Trastuzumab deruxtecan scheint auch jenseits von Lungenkrebs gut gegen solide Tumoren mit HER2-Mutationen zu wirken. Dafür sprechen die Daten einer offenen Pan-Tumor-Studie.

Mammakarzinom: Senken Statine das krebsbedingte Sterberisiko?

15.05.2024 Mammakarzinom Nachrichten

Frauen mit lokalem oder metastasiertem Brustkrebs, die Statine einnehmen, haben eine niedrigere krebsspezifische Mortalität als Patientinnen, die dies nicht tun, legen neue Daten aus den USA nahe.

Labor, CT-Anthropometrie zeigen Risiko für Pankreaskrebs

13.05.2024 Pankreaskarzinom Nachrichten

Gerade bei aggressiven Malignomen wie dem duktalen Adenokarzinom des Pankreas könnte Früherkennung die Therapiechancen verbessern. Noch jedoch klafft hier eine Lücke. Ein Studienteam hat einen Weg gesucht, sie zu schließen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.